Ellis Levine, MD Ellis Levine, MD

Ellis Levine

Medical Oncology
Top Doctors 2021

Dr. Levine is a Buffalo Spree Top Doctor! See all of our physicians who made this year's list.

Top Doctors 2021

Specializing In:

Bladder Cancer Breast Cancer Prostate Cancer Testicular Cancer

Special Interests:

Novel therapies for breast and urothelial cancer

About Ellis Levine


Roswell Park Comprehensive Cancer Center

  • Professor of Oncology
  • Chief, Breast Medicine
  • Hematology/Medical Oncology Fellowship Director
  • Department of Medicine

Jacobs School of Medicine and Biomedical Sciences, University at Buffalo

  • Professor of Medicine
  • Director, Hematology/Medical Oncology Fellowship Program


Education and Training:

  • MD - University of Pittsburgh, Pittsburgh, PA


  • University of Minnesota, Minneapolis, MN


  • University of Minnesota, Minneapolis, MN

Board Certification:

  • Internal Medicine, American Board of Internal Medicine
  • Medical Oncology, American Board of Internal Medicine

Honors & Awards:

  • 2005-2018 - America’s Top Doctors
  • 2018 - Susan G. Komen Hope Award for Upstate New York

Clinical Trials

Featured on Cancer Talk


Full Publications list on PubMed
  • Hinata N, Hussein AA, George S, Trump DL, Levine EG. Omar K, Dasgupta P, Khan MS, Hosseini A, Wiklund P, Guru KA: Impact of suboptimal neoadjuvant chemotherapy on perioperative outcomes and survival after robot-assisted radical cystectomy: A multicenter multinational study. BJU Int 119(4):605-611. 2017. [PMID: 27743481]
  • Adelson KB, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Han G, Villalona M, Ma CZ, Hershman D, Baar J, Klein P, Cigler T, Budd T, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL. Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D: Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: A New York Cancer Consortium Trial. NPJ Breast Cancer. 2016 Dec 14;2:16037. doi: 10.1038/npjbcancer.2016.37. eCollection 2016
  • Tsai M, Lo S, Audeh W, Qamar R, Budway R, Levine E, Whitworth P, Mavromatis B, Zon R, Oldham D, Untch S. Treece T, Blumencranz L, Soliman H, PROMIS Investigators Group: PROMIS Trial: The 70-gene signature provides independent risk stratification and treatment guidance for patients classified as intermediate by the 21-gene assay. JAMA Oncol. 2018 Jan 11;4(1):e173470. doi: 10.1001/jamaoncol.2017.3470. Epub 2018 Jan 11
  • Dhakal A, Matthews CM, Levine EG, Salerno KE, Zhang F, Takabe K, Early AP, Edge SB, O'Connor T, Khoury T, Young JS, Opyrchal M. Efficacy of Palbociclib Combinations in Hormone Receptor-Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment. Clin Breast Cancer. 2018 Dec;18(6):e1401-e1405. doi: 10.1016/j.clbc.2018.04.015. Epub 2018 Apr 28.
  • Hatem Soliman, Esther Rehmus, Varsha Shah, Gordan Srkalovic, Reshma Mahtani, Ellis Levine, Blanche Mavromatis, Jayanthi Srinivasiah, Mohamad Kassar, Robert Gabordi, Rubina Qamar, Sarah Untch, Heather M. Kling, Tina Treece, William Audeh, IMPACt investigators group: MammaPrint and BluePrint Molecular Subtyping Guide Treatment Decisions in Breast Cancer: results of the IMPACt trial (submitted)